These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10653382)

  • 21. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
    Small PM; Schecter GF; Goodman PC; Sande MA; Chaisson RE; Hopewell PC
    N Engl J Med; 1991 Jan; 324(5):289-94. PubMed ID: 1898769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).
    el-Sadr WM; Perlman DC; Matts JP; Nelson ET; Cohn DL; Salomon N; Olibrice M; Medard F; Chirgwin KD; Mildvan D; Jones BE; Telzak EE; Klein O; Heifets L; Hafner R
    Clin Infect Dis; 1998 May; 26(5):1148-58. PubMed ID: 9597244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antituberculous agents. Isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide.
    Van Scoy RE; Wilkowske CJ
    Mayo Clin Proc; 1983 Apr; 58(4):233-40. PubMed ID: 6834890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
    Cook PP; Maldonado RA; Yarnell CT; Holbert D
    Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy of tuberculosis.
    Pinsker KL; Koerner SK
    Am J Hosp Pharm; 1976 Mar; 33(3):275-83. PubMed ID: 769544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
    Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
    Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
    Jahng AW; Tran T; Bui L; Joyner JL
    Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculous hepatic abscess appearing after liver transplantation in a patient with human immunodeficiency virus and hepatitis B and C virus co-infection.
    Rodríguez-Framil M; Antela A; Prieto A; Otero E; Molina E; Varo E
    Transpl Infect Dis; 2011 Oct; 13(5):515-9. PubMed ID: 21395955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
    Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
    EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.